RECRUITINGINTERVENTIONAL
Infrared Photobiomodulation in Humans With Epilepsy
An Open Label Pilot Study of Infrared Photobiomodulation in Humans With Epilepsy
About This Trial
Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.
Who May Be Eligible (Plain English)
Who May Qualify:
- Drug resistant epilepsy
- Age 18 or older
- Average seizure rate of at least 2 seizures per month
- Accurate seizure diary with at least 3 months recorded
Who Should NOT Join This Trial:
- Implanted intracranial neurostimulation device (DBS or RNS)
- Intracranial shunt
- Skin photosensitivity
- Cancer on scalp
- Taking any medication that can cause photosensitivity
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Drug resistant epilepsy
* Age 18 or older
* Average seizure rate of at least 2 seizures per month
* Accurate seizure diary with at least 3 months recorded
Exclusion Criteria:
* Implanted intracranial neurostimulation device (DBS or RNS)
* Intracranial shunt
* Skin photosensitivity
* Cancer on scalp
* Taking any medication that can cause photosensitivity
Treatments Being Tested
DEVICE
photobiomodulation
a hat with infrared lights will be worn for 30 minutes daily for 6 months
Locations (1)
BIDMC
Boston, Massachusetts, United States